Semaglutide
Semaglutide is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our weight loss category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | Semaglutide |
|---|---|
| Classification | GLP-1 receptor agonist |
| Peptide type | Synthetic 31-amino-acid peptide |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | Approximately 4113.6 g/mol |
| Structure | 31-amino-acid GLP-1 analogue with a C18 fatty diacid chain for albumin binding and extended activity |
| Purity | ≥98% (HPLC-verified, batch-by-batch) |
| Form | Lyophilised peptide powder (vials) or ready-to-use solution (pens) |
| Appearance | White to off-white lyophilised powder (vials) prior to reconstitution |
| Presentation | Vials: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg. Pre-filled pens: 5 mg, 10 mg, 12 mg |
| Reconstitution | Reconstitute vials using bacteriostatic water or sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct light. For long-term storage of vials prior to reconstitution, freezing conditions are recommended. Pre-filled pens should be stored refrigerated and protected from light during transit and storage. Storage conditions are confirmed on the Certificate of Analysis supplied with each order. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-08-26. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The registrational work sits in three named programmes: SUSTAIN for the injection in type 2 diabetes, PIONEER for the oral form, and STEP for the 2.4 mg dose in weight management. STEP 1 randomised 1,961 adults without diabetes to 68 weeks of once-weekly subcutaneous semaglutide or placebo and measured percentage change in body weight. SELECT enrolled 17,604 adults with pre-existing cardiovascular disease and overweight or obesity and measured a three-point major adverse cardiovascular event composite over a mean 39.8 months. A 15-year medullary thyroid carcinoma registry was imposed as a required post-marketing study at original approval.
What is not established
The prescribing information records that semaglutide has not been studied in people with a history of pancreatitis, and that whether they are at higher risk is unknown. No regulator has assessed it for any use outside its approved indications.
What distinguishes Semaglutide
It is the only compound in this range with an approved solid oral dosage form, and the reason is formulation rather than peptide design. The tablets are co-formulated with salcaprozate sodium, a permeation enhancer that drives absorption in the stomach, giving an absolute oral bioavailability of roughly 0.4 to 1 per cent. The same molecule therefore holds two separate applications, NDA 209637 for the injection and NDA 213051 for the tablets, with different pharmacokinetics and different labelled administration instructions.
Sources
- US FDA. NDA 209637 approval letter, OZEMPIC (semaglutide) injection, 5 December 2017
- US FDA. NDA 213051 approval package, RYBELSUS (semaglutide) tablets, 20 September 2019
- European Medicines Agency. Wegovy, EPAR, EMEA/H/C/005422, authorised 6 January 2022
- European Medicines Agency. Ozempic, EPAR
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. SELECT
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
Semaglutide in supply terms
Semaglutide is registered under CAS 910463-68-2, with molecular formula C187H291N45O59 and a molecular weight of approximately 4113.6 g/mol. The backbone is a 31-amino-acid sequence classified as a GLP-1 analogue, carrying a C18 fatty diacid chain conjugated onto the peptide, a structural feature that distinguishes it chemically from unmodified GLP-1 fragments and places it in its own analogue subcategory. Two presentations are available. The vial format is a lyophilised, at least 98 percent HPLC-verified powder (white to off-white) reconstituted with bacteriostatic water or sterile laboratory-grade water, offered in 2mg, 5mg, 10mg, 15mg, 20mg and 30mg fills. The pen format is a ready-to-use solution in 5mg, 10mg and 12mg fills, with no reconstitution step required. Buyers comparing quotes across suppliers should confirm which presentation a price refers to, since a per-mg vial quote and a per-pen quote are not directly comparable without accounting for delivered volume and handling. Storage differs slightly by format: vials before reconstitution tolerate refrigeration at 2-8C with freezing recommended for extended holds, while pens should stay refrigerated and shielded from light throughout transit and storage. Certificate of Analysis documentation accompanies every order and specifies the verified storage window for that batch.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for Semaglutide and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Weight Loss
| Compound | Identifier | Presentation |
|---|---|---|
| AOD-9604 | 221231-10-3 | Vials: 5 mg. Pre-filled pens: 5 mg |
| Cagrilintide | C194H312N54O59 | Vials: 5 mg, 10 mg. Pre-filled ... |
| Retatrutide | C221H342N46O68 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
| Tirzepatide | 2023788-19-2 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
Questions
Supply, answered
Is Semaglutide available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy Semaglutide. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply Semaglutide as a second source?
Yes. Terms are agreed per compound, so you can add Semaglutide without moving anything else you buy elsewhere.
Request pricing for Semaglutide
Indicative volume and delivery country is enough to start. We reply within one working day.